Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Recurrent Stroke Prevention Clinical Outcome Study (RESPECTS)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2010 by Biomedis International Ltd.
Sponsor:
Information provided by:
Biomedis International Ltd.
ClinicalTrials.gov Identifier:
NCT01198496
First received: August 28, 2010
Last updated: July 29, 2012
Last verified: September 2010
  Purpose
  1. Objectives and Hypothesis

    1. Objectives:

      This study evaluates whether strict BP management is useful for the prevention of recurrent stroke.

      Hypertensive patients with history of stroke are treated with stepwise multi-drug therapy to achieve stricter BP target <120/80 mmHg in the strict BP control group and less stricter BP target <140/90 mmHg or <130/80 mmHg for patients with current DM/CKD/MI in the standard BP control group. The participants under the BP treatment achieving their respective BP target will be followed for recurrence of stroke. The study continues until the number of patients with the first recurrent stroke reaches a total of 330 between the two groups. The occurrence rates of recurrent stroke will be compared between the two groups.

    2. Hypotheses The incidence of recurrent stroke will be lower in a strict BP control group having lower BP target: <120/80 mmHg* than in a standard BP control group having BP target <140/90 mmHg or <130/80 mmHg for current DM/CKD/MI in patients with hypertension.
  2. Study design This will be a multicenter, randomized, open-label study. The study consists of a screening period, a titration period and a follow-up period. The screening period is a period between the date of consent and the enrollment date. Hypertensive patients with history of stroke are randomly assigned to either the strict BP control group having the target of <120/80 mmHg or the standard BP control group having the target of <140/90 mmHg without current DM, CKD or MI and <130/80 mmHg with current DM, CKD or MI. The titration period is the period finding a treatment which achieves target BP, and 24 weeks at maximum. Patients will be treated with stepwise multi-drug therapy using an angiotensin-receptor antagonist, diuretic, calcium channel blocker and aldosterone antagonist. The participants will be observed under the BP management for their respective BP target. The study will be continued until the number of patients with the first recurrent stroke reaches a total of 330 between two groups. The follow-up period will be 3 years.

The recurrent rates of stroke in both groups will be compared from various aspects, and strict BP management will be investigated on the usefulness in prevention of recurrent stroke.


Condition Intervention Phase
Hypertension
Stroke
Blood Pressure
Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke

Resource links provided by NLM:


Further study details as provided by Biomedis International Ltd.:

Primary Outcome Measures:
  • the prevention of recurrent stroke. [ Time Frame: Until the first recurrent stroke reaches a total of 339 between the two groups ] [ Designated as safety issue: Yes ]
    Hypertensive patients with history of stroke are treated with stepwise multi-drug therapy to achieve BP target less than 120/80 mmHg in the strict BP group and BP target less than 140/90 mmHg or less than 130/80 mmHg for patients with DM/CKD/old MI in the standard BP group. The participants under the BP treatment achieving their respective BP target will be followed for recurrence of stroke. The study continues until the number of patients with the first recurrent stroke reaches a total of 339 between the two groups.


Secondary Outcome Measures:
  • The incidence of events other than stroke [ Time Frame: Until the first recurrent stroke reaches a total of 339 between the two groups ] [ Designated as safety issue: Yes ]

    Under the strict BP control, not only the recurrence of stroke but also occurrence of cardiovascular events (such as myocardial infarction and heart failure), angioplasty, and death will be reduced.

    Separate hypothesis: Additionally, occurrence and exacerbation of dementia is also decreased under the strict BP control in comparison with the standard control.



Estimated Enrollment: 5000
Study Start Date: October 2010
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Blood pressure

The incidence of recurrent stroke will be lower in a strict BP control group having lower BP target: less than 120/80 mmHg* than in a standard BP control group having BP target less than 140/90 mmHg or less than 130/80 mmHg for current DM/CKD/old MI in patients with hypertension.

  • This study uses BP target: less than 120/80 mmHg that is sat up for this study rather than the BP target recommended in the Guidelines for the management of hypertension, Japanese Society of Hypertension 2009.
  • BP management is strongly recommended in patients with hypertension, DM, and/or CKD for prevention of recurrent stroke in the Japanese guidelines for the management of stroke 2009.
Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
<Study drugs and treatment steps> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
Other Names:
  • candesartan cilexetil
  • valsartan
  • telmisartan
  • olmesartan medoxomil

Detailed Description:

Rationale for Study Duration Predicting that strict BP control reduces the relative risk of recurrent stroke by 30% during the planned observation period of 3 years, the number of participants necessary to detect the recurrent stroke with rate of 2.5%/year and 7.5%/3 years is 2482 patients per group with a detection power of 90% and α-error of 0.05. A drop-out rate is estimated as 20%.

Therefore, the study will be continued for 3 years until a total of 330 patients with recurrent stroke in both groups are identified.

Rationale for Dosing Regimen One of ARB, losartan, is chosen for Step 1 therapy, because angiotensin II receptor blocker (ARB) is preferred as the first line of anti-hypertensives. Furthermore, a stepwise combination therapy of BP lowering drugs diuretic, hydrochlorothiazide, and calcium channel blocker, amlodipine, will be used, because the Japanese guidelines recommend the combination for BP control in prevention of recurrent stroke. (Step 2 to Step 5). Finally (as Step 6), a selective aldosterone antagonist, spironolactone, will be added for the treatment of with refractory hypertensive patients whose BP does not reach to the target.

Treatment Plan The dosages of study drugs will be determined according to the package insert for the drug.

Patients who are not treated with antihypertensive agent or treated with one antihypertensive agent at enrollment will start from Step 1. Patients who are treated with two antihypertensive agents at enrollment will start from Step 2.

In principle, treatment duration will be for 4 weeks at each step.

  Eligibility

Ages Eligible for Study:   50 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Participants include those with essential hypertension and history of stroke who satisfy the following criteria:

  • Outpatient
  • Onset of stroke(cerebral infarction/cerebral hemorrhage) occurred between 30 days and 3 years prior to the date of consent.
  • Drug adherence is ≧80% during the screening period.
  • Mean of 2 baseline BP measurements(measured at outpatient clinic) within 30 days prior to the date of consent is either 180 >SBP ≧130 mmHg or 110 >DBP ≧80 mmHg (untreated -3 anti hypertensive agents patients).
  • Cerebral infarction with severity 3 or less in the modified Rankin scale.

Exclusion Criteria:

Patient who meets any one of the following criteria is excluded from the study.

  • Women who are pregnant, are possible pregnant, or are breastfeeding
  • Possible secondary hypertension
  • Severe hypertension (grade III or greater) with baseline SBP ≧180 mmHg or DBP ≧110 mmHg)
  • Myocardial infarction or undergoing angioplasty occurred within 3 months prior to the screening.
  • Current or previous heart failure with NYHA classification class III or more, or EF less than 35%
  • Severe bilateral carotid stenosis or major cerebral artery occlusion
  • Severe paralysis due to stroke (modified Rankin scale ≧ 4 )
  • Current renal dysfunction (serum Cr ≧ 2.0 mg/dL right before the date of consent)
  • Current hepatic dysfunction with AST or ALT value ≧ 100 IU/mL right before the date of consent
  • Refractory hypertension treated with four or more antihypertensive drugs
  • Hypersensitivity or allergy to losartan and other angiotensin II receptor blockers, hydrochlorothiazide, amlodipine or sulfonamide derivative
  • Major surgery planned during the study period
  • Participants of other clinical studies within the last 30 days
  • Current malignancy (previous malignancy within 5 years after the end of treatment) excluding squamous-cell skin cancer
  • Previous and current subarachnoid hemorrhage
  • Definitive dementia 12) (based on a clinical diagnosis)
  • Patients who have difficulty in signing consent or who do not agree to the provided consent
  • Patients who are judged to be unsuitable for participating the study by the primary investigator or sub-investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01198496

Contacts
Contact: Hiroko Usami, PhD 81-1-3-6252-3282 hiroko-u@biomedis.co.jp

Locations
Japan
Jichi Medical Univercity Recruiting
Shimotsuke, Tochigi, Japan, 329-0498
Contact: Kazuyuki Shimada, MD       kazuyuki@jichi.ac.jp   
Principal Investigator: Kazuomi Kario, MD         
Sponsors and Collaborators
Biomedis International Ltd.
Investigators
Study Chair: Kazuyuki Shimada, MD RESPECT Study Group
  More Information

Additional Information:
No publications provided

Responsible Party: Kazuyuki Shimada/Board chairperson, RESPECT Study Group
ClinicalTrials.gov Identifier: NCT01198496     History of Changes
Other Study ID Numbers: RESPECT 1, UMIN000002851
Study First Received: August 28, 2010
Last Updated: July 29, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Biomedis International Ltd.:
hypertension
stroke
blood pressure

Additional relevant MeSH terms:
Cerebral Infarction
Hypertension
Stroke
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Vascular Diseases
Amlodipine
Candesartan cilexetil
Losartan
Olmesartan medoxomil
Spironolactone
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Calcium Channel Blockers
Cardiovascular Agents
Diuretics
Diuretics, Potassium Sparing
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Membrane Transport Modulators
Mineralocorticoid Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents

ClinicalTrials.gov processed this record on November 20, 2014